Medical imaging and radiology
Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directorySpectral AI DeepView medical AI product profile
AI-enabled multispectral imaging system for burn wound assessment that received FDA De Novo classification for the DeepView AI System in May 2026.
Medical imaging and radiology
Best fit
Burn-care organizations evaluating regulated predictive imaging for early burn wound healing assessment with specialist review.
- Primary use case
- AI-enabled multispectral wound imaging for burn wound healing assessment and treatment-planning support
- Audience
- Burn centers, trauma centers, emergency departments, wound care researchers, and medical device governance teams
- Risk level
- High
- Pricing signal
- Commercialization timing and pricing should be verified with Spectral AI after FDA De Novo clearance.
- Official sources
- 3 official sources
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Spectral AI DeepView as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as regulated medical-device software and match use to the FDA De Novo indication, labeling, trained users, and burn-care setting. |
|---|---|
| Privacy | Review imaging data flow, device connectivity, support access, storage, retention, BAA terms, and whether research or commercial deployments use different data terms. |
| Evidence | Review pivotal and post-market evidence for healing prediction, false reassurance risk, timing after injury, skin tone, burn depth, and effect on grafting decisions. |
| Workflow | Best governed as burn-specialist decision support with documented imaging timing, interpretation, escalation, treatment planning, and outcome monitoring. |
Where Spectral AI DeepView fits
Spectral AI describes DeepView as a predictive AI wound imaging system using multispectral imaging; FDA's De Novo database lists DeepView AI System, DEN250028, with a May 21, 2026 decision date, and Spectral AI announced De Novo clearance for the burn indication on May 26, 2026.
Not for: General chronic wound assessment, use outside the cleared burn indication, or treatment decisions without burn-specialist clinical judgment.
What to verify before using Spectral AI DeepView
- FDA De Novo DEN250028, indication, labeling, contraindications, user training, and commercial availability for the intended burn-care setting.
- Whether the workflow applies to burn centers, trauma centers, emergency departments, or research use only in your deployment.
- Image data handling, cloud or device processing, retention, integration, audit logs, and BAA or device-data terms.
- Local validation for burn type, skin tone, timing after injury, grafting decisions, false positives, false negatives, and clinician response.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.spectral-ai.com
- www.globenewswire.com / news-release / 2026
- www.accessdata.fda.gov / scripts / cdrh
Related medical AI products
Medical imaging and radiology
Viz.ai
AI-powered care coordination platform with imaging-driven alerts across therapeutic areas.
Medical imaging and radiology
Ferrum Health
Clinical AI governance and deployment platform for health systems adopting multiple imaging or clinical AI models.
Medical imaging and radiology
Blackford Platform
Enterprise medical imaging AI platform for evaluating, deploying, routing, and monitoring multiple radiology AI applications.